Esperion Therapeutics | ESPR - Betriebsaufwand





Betriebsaufwand Veränderung Datum
AbbVie USD 10.27B 538M 2026-03
Alnylam Pharmaceuticals USD 898.54M 66.78M 2026-03
Alterity Therapeutics Limited AUD 8.67M 893.38K 2025-12
Amarin USD 51.48M 113K 2025-12
Amgen USD 4.78B 1.12B 2026-03
Biogen USD 1.96B 69.6M 2026-03
BioMarin Pharmaceutical USD 636.56M 39.61M 2026-03
Cipla INR 59.27B 1.71B 2026-03
CSL USD 5.7B 2.82B 2025-12
Cytokinetics USD 200.58M 4.46M 2026-03
Daiichi Sankyo JPY 468.57B 15.34B 2025-12
Eli Lilly USD 10.02B 285M 2026-03
Esperion Therapeutics USD 83.21M 14.06M 2025-12
Geron USD 52.07M 6.73M 2026-03
Grifols EUR 1.99B 217.4M 2025-12
Halozyme Therapeutics USD 192.19M 18.88M 2026-03
Heron Therapeutics USD 40.55M 1.46M 2025-12
Ionis Pharmaceuticals USD 364M 54M 2026-03
Merck USD 18.17B 8.01B 2026-03
Minerva Neurosciences USD 4.52M 155.46K 2024-12
Moderna USD 1.78B 242M 2026-03
Nektar Therapeutics USD 40.9M 44.19M 2025-12
Pfizer USD 90.1B 77.19B 2026-03
PTC Therapeutics USD 226.66M 19.64M 2026-03
Puma Biotechnology USD 49.26M 3.2M 2024-06
Regeneron Pharmaceuticals USD 31.42B 28.44B 2026-03
Sanofi EUR 9.31B 1.2B 2026-03
Sarepta Therapeutics USD 372.37M 480.65M 2026-03
United Therapeutics USD 5.9B 5.1B 2026-03
Vanda Pharmaceuticals USD -1.14B 1.6B 2025-12